SAB Biotherapeutics (SABS) Income towards Parent Company (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Income towards Parent Company data on file, last reported at -$46.5 million in Q1 2026.

• Quarterly Income towards Parent Company fell 323.92% year-over-year to -$46.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$84.8 million (down 121.91% YoY) and the FY2025 annual result came in at -$73.6 million, down 71.9% from the prior year.
• Income towards Parent Company slipped to -$46.5 million in Q1 2026, from -$15.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $985863.0 in Q1 2022 to a low of -$46.5 million in Q1 2026.
• A 5-year average of -$11.1 million and a median of -$7.8 million in 2022 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company sank 845.93% — and 2024, when it jumped 58.11%.
• Tracing SABS's Income towards Parent Company over 5 years: stood at -$7.8 million in 2022, then slumped by 191.21% to -$22.9 million in 2023, then jumped by 58.11% to -$9.6 million in 2024, then sank by 58.04% to -$15.1 million in 2025, then plunged by 207.34% to -$46.5 million in 2026.
• The last three Income towards Parent Company figures came in at -$46.5 million (Q1 2026), -$15.1 million (Q4 2025), and -$12.8 million (Q3 2025), per Business Quant data.